Luis Gil De Gómez Sesma

Luis Gil-de-Gómez is Assistant Professor at University of Cantabria supported by a Beatriz Galindo Fellowship. Over a variety of research projects, Dr. Gil-de-Gómez has developed a research portfolio in the study of how metabolism shapes the innate and adaptive immune response in inflammation and diverse diseases, including Alzheimer’s disease, malnutrition, and cancer. Dr. Gil-de-Gómez has experienced in chromatography, mass spectrometry and flow cytometry techniques. Based on these platforms, he has worked on a wide array of projects: his PhD was based on lipidomic profiling in relation to inflammation, allowing the characterization of lipid mediators involved in innate immune responses. His next project, at Biocross Inc., was a large study that comprised seven European hospitals and more than 250 participants. The aim was to develop a diagnosis method for Alzheimer's disease by identifying alterations in plasma metabolites that persist throughout the continuum of Alzheimer´s disease pathophysiology. His postdoctoral experience at University of Pennsylvania combined metabolomic analysis of immune cells and the study of the interaction of the microbiome and its derived metabolites with the adaptive immune response. His next project at Children´s Hospital of Philadelphia (CHOP) was focused on improving efficacy of currently available single Ag-targeted therapies by inducing recognition of non-immunogenic leukemia antigens. Dr. Gil-de-Gómez joined CCCR Biorepository and Registry at CHOP in 2020 as a Research Scientist. He led a team of 4 people focused on the collection and analysis of high clinically valuable patient specimens to support new and ongoing research efforts into understanding childhood cancer and develop new therapeutic approaches. Dr. Gil-de-Gómez has published 17 articles and has a H-index of 14. In 2020 he was invited to work as guest editor for Metabolites in the Special Issue "Advances in Lipidomics: Biomedicine, Nutrition and Methodology". His current research is focused on the study of immunometabolism as a source of biomarkers and novel therapeutic targets.